NDAQ:ACOG - Post Discussion
Post by
XeniaTechie on Nov 05, 2021 12:20pm
Alpha Cognition big potential to take massive ADmarket share
Alpha Cognition has immense potential to capture major market share of ALZ treatment, a $355B market expected to grow to $1.1T by 2050. A-1062 taps into the gap where 8/10 #AD patients cease treatment due to side-effects. $ACOG.v is on track for rapid approval to market. The pivotal trial stages will begin Q3 '21 with top-line results expected before end of '21. https://www.alphacognition.com/our-approach/alpha-1062/
Be the first to comment on this post